Keytruda Improves Survival in Triple-Negative Breast Cancer

Keytruda Improves Survival in Triple-Negative Breast Cancer

September 15, 2024

People diagnosed with early-stage triple-negative breast cancer who received the immunotherapy Keytruda (chemical name: pembrolizumab) along with chemotherapy before and after surgery had better event-free survival — how long they lived without the cancer coming back. Read more…